Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 3711 publications.

Copley-Merriman K, Doward L, Hawe E, Cope S. Clinical trial design, beyond the regulatory. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Buck PM, Masaquel C. The most heavily managed drug categories on Part D formularies. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M. Interventions to improve adherence and persistence to oral medication: a targeted literature review. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Pladevall-Vila M, Ziemiecki R, Johannes CB, Khan AM, Mines D, Ebert N, Kovesdy CP, Thomsen RW, Baak BN, Garcia-Sempere A, Kanegae H, Coleman CI, Walsh M, Andersen IT, Bernal CR, Cabaninas CR, Christiansen CF, Farjat AE, Gay A, Gee P, Herings RMC, Hurtado I, Kashihara N, Kristensen FPB, Liu F, Okami S, Overbeek JA, Beest FJAP, Yamashita S, Yano Y, Layton JB, Vizcaya D, Oberprieler NG. Clinical profile and treatment patterns in individuals with type 2 diabetes and chronic kidney disease who initiate a GLP-1 receptor agonist: a multinational cohort study. Diabetes Ther. 2025 May;16(5):931-54. doi: 10.1007/s13300-025-01717-8

Yano Y, Okami S, Kanegae H, Oberprieler NG, Johannes C, Yamashita S, Yoshikawa-Ryan K, Kovesdy CP, Vizcaya D, Kashihara N. Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-a hospital-based cohort study in Japan. Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16394

Stempniewicz N, Davenport E, Wang J, Sweeney C. Herpes zoster vaccination: primary care provider knowledge, attitudes, and practices. Hum Vaccin Immunother. 2025 Apr 18;21(1):2488093. doi: 10.1080/21645515.2025.2488093

Tamhankar MA, Raza S, Brutsaert E, Urdaniz E, Vainilovich Y, Heyes A, Gildea L, Sales-Sanz M. The burden of illness in thyroid eye disease: current state of the evidence. Front Ophthalmol. 2025 Apr 16;5. doi: 10.3389/fopht.2025.1565762

Rao S, McQuay LJ, Forns J, MacKay R, Danysh HE, Doshi D, Abler V, Anthony MS, Layton JB. Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update. Drug Saf. 2025 Apr 9. doi: 10.1007/s40264-025-01543-8

Horn EK, La EM, Bektas M, Khan S, Gerber SI. Disparities in respiratory syncytial virus risk factors, diagnosis, and outcomes in adults by race, ethnicity, and other social determinants of health in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):459-71. doi: 10.1080/14737167.2024.2441867

Garcia de Albeniz Martinez X. Validate study variables to reduce misclassification bias: recent tools and research needs. Presented at the ARS Toscana Webinar; March 27, 2025. Florence, Italy.

Jedynak P, Bustamante M, Rolland M, Mustieles V, Thomsen C, Sakhi AK, Sabaredzovic A, Foraster M, Gascon M, Gomez-Roig MD, Llurba E, Rivas I, Ouellet-Morin I, Bayat S, Lyon-Caen S, Pozo OJ, Vrijheid M, Sunyer J, Slama R, Dadvand P, Philippat C. Prenatal exposure to synthetic phenols assessed in multiple urine samples and dysregulation of steroid hormone homeostasis in two European cohorts. Environ Health Perspect. 2025 Mar 21. doi: 10.1289/EHP15117

Zubizarreta-Arruti U, Bosch R, Soler Artigas M, Cabana-Dominguez J, Llonga N, Carabi-Gassol P, Macias-Chimborazo V, Vilar-Ribo L, Ramos-Quiroga JA, Pagerols M, Prat R, Rivas C, Pagespetit E, Puigbo J, Espanol-Martin G, Raimbault B, Valentin A, Sunyer J, Foraster M, Gascon M, Casas M, Ribases M, Alemany S. Associations between air pollution and surrounding greenness with internalizing and externalizing behaviors among schoolchildren. Child Adolesc Ment Health. 2025 Mar 21. doi: 10.1111/camh.12772

Vila Guilera J, Abellan A, Garcia de Albeniz X, Houghton K. External control arm studies in marketing authorisation applications submitted to the European Medicines Agency: a review of study design features and methods. Presented at the Drug Information Association (DIA) Europe 2025; March 18, 2025. Basel, Switzerland.

Aguilar-Lacasana S, Cosin-Tomas M, Raimbault B, Gomez-Herrera L, Sanchez O, Zanini MJ, Capdevila RP, Foraster M, Gascon M, Rivas I, Llurba E, Gomez-Roig MD, Sunyer J, Bustamante M, Vrijheid M, Dadvand P. Epigenome-wide association study of pregnancy exposure to green space and placental DNA methylation. Environ Res. 2025 Mar 4;274:121286. doi: 10.1016/j.envres.2025.121286

Aguado J, Gutierrez L, Forns J, Vila Guilera J, Rothman KJ, Garcia-Albeniz X. Effect of different durations of treatment with antihypertensive drugs with anticholinergic effects on the risk of dementia: a target trial emulation study. Am J Epidemiol. 2025 Mar 4;194(3):691-8. doi: 10.1093/aje/kwae263

Khanji C, Nuabor W, Gould T, Kim HK, Barrows S, Herbel B, Njue A. Systematic literature review of outcomes associated with adherence to haemophilia drug therapy. Haemophilia. 2025 Mar;31(2):187-206. doi: 10.1111/hae.15153

Layton JB, Anderson-Smits C, Huang Z, Ay H, Spalding W, Khokhar B, Zhou J, Bennett L, Anthony MS. A comparative real-world study evaluating the safety of immune globulin infusion (human) 10% solution and other intravenous immunoglobulin therapies for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Pharmacoepidemiol Drug Saf. 2025 Mar;34(3):e70124. doi: 10.1002/pds.70124

Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Plain language summary of mortality rates of patients with Parkinson's disease psychosis who were treated either with pimavanserin or with different second-generation (atypical) antipsychotics. Futur Neurol. 2025 Feb 28;20(1). doi: 10.1080/14796708.2025.2463315

Perrone RD, Garbinsky D, Nunna S, Gandhi HK, Fernandes AW, Burgos G, Olopoenia A, DeCongelio M, Maculaitis MC, Zhou X. Effectiveness of tolvaptan for autosomal dominant polycystic kidney disease in US clinical practice with comparison to historical control data. Kidney Med. 2025 Feb 27;7(5):100988. doi: 10.1016/j.xkme.2025.100988

Kovesdy CP, Ebert N, Vizcaya D, Walsh M, Kosiborod MN, Layton JB, Ziemiecki R, Johannes CB, Pladevall-Vila M, Gee PO, Jefferson N, Chicoye A, Lopes M, Thapa BB, Curhan G, Rangel L, Bhartia M, Liu F, Farjat AE, Oberprieler NG. Change in urine albumin-creatinine ratio and occurrence of hyperkalemia in patients initiating finerenone in the United States: a cohort study from the FOUNTAIN platform. Nephron. 2025 Feb 27;1-26. doi: 10.1159/000543923

Murillo ER, Mora JRM, Bachiller MM, Santiago LG, Braque NN, Bravo MO. Factors associated with low adherence to inhaled therapy in patients with chronic respiratory diseases: a cross-sectional study. BMC Pulm Med. 2025 Feb 27;25(1):94. doi: 10.1186/s12890-025-03563-7.

Weisel K, Mateos MV, Landgren O, Leleu X, Quach H, Bennett L, Talpes M, Majer I, Patel S, Usmani SZ. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with carfilzomib, dexamethasone, and daratumumab versus carflizomib and dexamethasone: an analysis of patient-reported outcomes from the phase 3 CANDOR trial. Clin Lymphoma Myeloma Leuk. 2025 Feb 19. doi: 10.1016/j.clml.2025.02.005

Johannes CB, Ziemiecki R, Pladevall-Vila M, Ebert N, Kovesdy CP, Thomsen RW, Baak BN, Garcia-Sempere A, Kanegae H, Coleman CI, Walsh M, Andersen IT, Rodriguez Bernal C, Robles Cabaninas C, Christiansen CF, Farjat AE, Gay A, Gee P, Herings RMC, Hurtado I, Kashihara N, Kristensen FPB, Liu F, Okami S, Overbeek JA, Penning-van Beest FJA, Yamashita S, Yano Y, Layton JB, Vizcaya D, Oberprieler NG. Clinical profile and treatment adherence in patients with type 2 diabetes and chronic kidney disease who initiate an SGLT2 inhibitor: a multi-cohort study. Diabetes Ther. 2025 Feb;16(2):205-26. doi: 10.1007/s13300-024-01671-x

Abellan A, Burn E, Trinh NTH, Burkard T, Callahan A, Fernandez-Bertolin S, Hurley E, Rodriguez C, Segundo E, Morales DR, M E Nordeng H, Duarte-Salles T. Expanding the OMOP common data model to support perinatal research in network studies. Pharmacoepidemiol Drug Saf. 2025 Feb;34(2):e70106. doi: 10.1002/pds.70106

Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996

Wright GC, Zueger PM, Copley-Merriman K, Khan S, Costello J, Krumbach A, Reddy P, Tanjinatus O, Wells AF. Health disparities in rheumatology in the United States. Open Access Rheumatol. 2025 Jan 9;17:1-12. doi: 10.2147/OARRR.S493457

Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW. Tolvaptan and autosomal dominant polycystic kidney disease progression in individuals aged 18–35 years: a pooled database analysis. Kidney Med. 2025 Jan;7(1):100935. doi: 10.1016/j.xkme.2024.100935

Samuelsson K, Rivas I, Raimbault B, Dominguez A, Galmes T, Valentin A, Foraster M, Gascon M, Persavento C, Psyllidis A, Gomez Roig MD, Olive EL, Nieuwenhuijsen MJ, Helbich M, Sunyer J, Dadvand P. A comprehensive GPS-based analysis of activity spaces in early and late pregnancy using the ActMAP framework. Health Place. 2025 Jan;91:103413. doi: 10.1016/j.healthplace.2025.103413

La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796

Pistillo A, Warkentin S, Abellan A, de Bont J, Ranger T, Perez-Crespo L, Cirach M, Perramon-Malavez A, Khalid S, Nieuwenhuijsen M, Vrijheid M, Duarte-Salles T. Residential relocation and changes in patterns of environmental exposures by health determinants among children and adolescents in Catalonia, Spain. Environ Res. 2024 Dec 15;263(Pt 2):120152. doi: 10.1016/j.envres.2024.120152

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the 2024 Parkinson Study Group (PSG) 33rd Annual Meeting; December 5, 2024. Nashville, TN. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.

D'Souza V, Bhogal P, Njue A. Impact of the innovative licensing and access pathway (ILAP) designation on regulatory and health technology assessment (HTA) outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S312. doi: 10..1016/j.jval.2024.10.1623

Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J, Zhou X, Gnanasakthy A, Taylor K, Yusuf A, Maher I, Jamotte A, Kang YK. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095

Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, Pathak S, Anthony MS, Layton JB. Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis by antipsychotic treatment status in the United States. J Alzheimers Dis. 2024 Dec;102(4):1260-70. doi: 10.1177/13872877241297361

Leonard C, Unsworth H, Warttig S, Gildea L, Mordin M, Ling C. HTA considerations for large language models in healthcare. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730

Leonard C, Bhogal P, Menon AP, Ling C, Mordin M. HTA requirements for medical technologies in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S494. doi: 10.1016/j.jval.2024.10.2513

Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the economic burden of hemophilia A and B. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S629. doi: 10.1016/j.jval.2024.10.3157

Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the humanistic burden of hemophilia A and B. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S613. doi: 10.1016/j.jval.2024.10.3082

Yubin Sohn A, Khanji C, Nuabor W, Gould T, Kim HK, Barrows SM, Herbel B, Njue A. Effect of adherence to hemophilia drug therapy on outcomes: a systematic literature review. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S634. doi: 10.1016/j.jval.2024.10.3181

Gaber CE, Ghazarian AA, Strassle PD, Ribeiro TB, Salas M, Maringe C, Garcia-Albeniz X, Wyss R, Du W, Lund JL. De-mystifying the clone-censor-weight method for causal research using observational data: a primer for cancer researchers. Cancer Med. 2024 Dec;13(23):e70461. doi: 10.1002/cam4.70461

Dominguez A, Dadvand P, Cirach M, Arevalo G, Barril L, Foraster M, Gascon M, Raimbault B, Galmes T, Gomez-Herrera L, Persavento C, Samuelsson K, Lao J, Moreno T, Querol X, Jerrett M, Schwartz J, Tonne C, Nieuwenhuijsen MJ, Sunyer J, Basagana X, Rivas I. Development of land use regression, dispersion, and hybrid models for prediction of outdoor air pollution exposure in Barcelona. Sci Total Environ. 2024 Dec 1;954:176632. doi: 10.1016/j.scitotenv.2024.176632

Khan S, Copley-Merriman K, Heyes A, Hawe E, Hartley L, Kallmes K. Qualitative and quantitative evidence synthesis strategies to support JCA and IRA submissions. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S382. doi: 10.1016/j.jval.2024.10.1970

Ling C, Hawe E, Stevenson A, Low EW. Giving voice to rare diseases during joint clinical assessment (JCA). Presented at the ISPOR Europe 2024; November 20, 2024. Barcelona, Spain.

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the Neuroscience Education Institute (NEI) Congress 2024; November 8, 2024. Colorado Springs, CO.

Halsby K, Gildea L, Madhava H, Angulo FJ, Pilz A, Erber W, Moisi J, Schley K, Colosia A, Sellner J. Clinical manifestations and outcomes of tick-borne encephalitis: a systematic literature review. Ticks Tick Borne Dis. 2024 Nov 4;15(6):102407. doi: 10.1016/j.ttbdis.2024.102407

Knox B, Guil-Oumrait N, Basagana X, Cserbik D, Dadvand P, Foraster M, Galmes T, Gascon M, Dolores Gomez-Roig M, Gomez-Herrera L, Smastuen Haug L, Llurba E, Marquez S, Rivas I, Sunyer J, Thomsen C, Julia Zanini M, Bustamante M, Vrijheid M. Prenatal exposure to per- and polyfluoroalkyl substances, fetoplacental hemodynamics, and fetal growth. Environ Int. 2024 Nov;193:109090. doi: 10.1016/j.envint.2024.109090

Xie J, Lopez-Guell K, Dedman D, Duarte-Salles T, Kolde R, Lopez-Blasco R, Martinez A, Mercier G, Abellan A, Arinze JT, Cuccu Z, Delmestri A, Delseny D, Khalid S, Kim C, Kim JW, Kostka K, Loste C, Mateu L, Mayer MA, Melendez-Cardiel J, Mercade-Besora N, Mosseveld M, Nishimura A, Nordeng HME, Oyinlola JO, Perez-Crespo L, Pineda-Moncusi M, Ramirez-Anguita JM, Trinh NTH, Uuskula A, Valdivieso B, Burkard T, Burn E, Catala M, Prieto-Alhambra D, Paredes R, Jodicke AM. Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data. EClinicalMedicine. 2024 Oct 30;77(102903). doi: 10.1016/j.eclinm.2024.102903

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Comparing the mortality risk of patients on FDA-approved treatment for Parkinson's disease psychosis, pimavanserin, vs other antipsychotics. Poster presented at the 37th Annual Psych Congress; October 29, 2024. Boston, MA. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.

Broughton EI, Bektas M, Colosia A, Fernandez M, Kuper K, Al-Taie A, Kotb REM. Assessing the global economic burden of complicated urinary tract infections. Poster presented at the IDWeek 2024; October 18, 2024. Los Angeles, California.